Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE versus METOPROLOL TARTRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE versus METOPROLOL TARTRATE.
BETAPACE vs METOPROLOL TARTRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
Competitive beta-1 adrenergic receptor antagonist with weak beta-2 blocking activity; reduces heart rate, contractility, and AV conduction.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
Initial dose 100 mg daily in divided doses (e.g., 50 mg twice daily) orally; may increase weekly up to 200-450 mg daily in 2-3 divided doses.
None Documented
None Documented
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
3–4 hours (terminal) in healthy adults; prolonged to 7–8 hours in severe hepatic impairment; no change in renal impairment.
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Renal: 95% as metabolites, <5% unchanged. Fecal: negligible.
Category C
Category C
Beta-Blocker
Beta-Blocker